George S. Baillie

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Development of a Nanoscale Protein-Protein Mapping of PDE4 Interface-Disrupting Peptides.

Development of a Nanoscale Protein-Protein Mapping of PDE4 Interface-Disrupting Peptides.

Journal: Nano letters

Published: April 17, 2026

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Journal: Cytotherapy

Published: April 01, 2026

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.

Journal: British journal of pharmacology

Published: November 09, 2025

KTX207-mediated PDE4D degradation disrupts tumour cell migration, invasion, and angiogenic potential.

KTX207-mediated PDE4D degradation disrupts tumour cell migration, invasion, and angiogenic potential.

Journal: Cell communication and signaling : CCS

Published: October 26, 2025

A connexin 43 targeting peptide prevents blood vessel neointima formation.

A connexin 43 targeting peptide prevents blood vessel neointima formation.

Journal: bioRxiv : the preprint server for biology

Published: October 03, 2025

Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disorders.

Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disorders.

Journal: Journal of translational autoimmunity

Published: June 10, 2025

Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.

Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.

Journal: The FEBS journal

Published: March 25, 2025

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells.

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells.

Journal: Molecular therapy. Oncology

Published: February 27, 2025

Withdrawal: RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with βArrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the β2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells.

Withdrawal: RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with βArrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the β2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells.

Journal: The Journal of biological chemistry

Published: February 17, 2025

Quantification and structure-function analysis of calpain-1 and calpain-2 protease subunit interactions.

Quantification and structure-function analysis of calpain-1 and calpain-2 protease subunit interactions.

Journal: The Journal of biological chemistry

Published: February 10, 2025

Blocking the Dkk1-LRP6 interaction prevents acute amyloid-β-driven cognitive impairment.

Blocking the Dkk1-LRP6 interaction prevents acute amyloid-β-driven cognitive impairment.

Journal: Cellular signalling

Published: January 24, 2025

Ang-(1-7) and ET-1 Interplay Through Mas and ETB Receptor Interaction Defines a Novel Vasoprotective Mechanism.

Ang-(1-7) and ET-1 Interplay Through Mas and ETB Receptor Interaction Defines a Novel Vasoprotective Mechanism.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 05, 2024

Showing 1-12 of 148

Last Updated: 09/26/2026